These results revealed that the point mutation that activated PPARγ or RXRα mutation that acted through PPARγ-dependent pathways 22 provide convincing evidence for identifying PPARγ as a proto-oncogene in bladder cancer and highlight PPARγ as a promising therapeutic target for luminal MIBC 21. Here, RXRA is linked to urinary bladder carcinoma.